DynamiCure Announces Appointment of Industry Veteran Peter Lasky as…

DynamiCure Announces Appointment of Industry Veteran Peter Lasky as…

Facebook
Twitter
LinkedIn

WALTHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) — DynamicCure, a private biopharmaceutical company translating pioneering discoveries in immune normalization into a pipeline of innovative therapeutic antibody candidates, today announced the appointment of Peter Lasky as Chief People Officer. In this role, Mr. Lasky leads all people-related functions with a focus on innovation and collaboration, as well as talent acquisition, leadership development, diversity, inclusion and ESG (environmental, social and governance).

“Peter brings extensive experience in the biopharmaceutical industry, having served as a key member of leadership teams building and sustaining resilient cultures and engaged workforces,” said Oliver Rosen, MD, President and Chief Medical Officer of DynamiCure. “Having previously worked with Peter, I am delighted that he is joining us at DynamiCure and have the utmost confidence in his ability to guide us through our development and growth as we continue to bring novel therapies to the benefit of patients with a broad spectrum driving variety of cancers and autoimmune diseases.”

Commenting on the news, Mr. Lasky also said, “I am very impressed with the DynamiCure team and all they have accomplished and am honored to have been appointed as their first Chief People Officer. This is a major turning point for the Company as we prepare to begin clinical development of our lead candidate and I look forward to maintaining the passion that has driven the team to date and advancing our mission to serve patients with significant unmet medical needs need to help.”

Most recently, Mr. Lasky served as Senior Vice President, Human Resources at Deciphera Pharmaceuticals and previously held similar positions at Wave Life Sciences, Sekisui Diagnostics and Shire Pharmaceuticals. Earlier in his career, he also held leadership positions in human resources at AstraZeneca, Millipore Corporation and Genetics Institute. Mr. Lasky has on many…



Source story

More to explorer